CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'ellé). This report covers the quarterly period ended May 31, 2010, and the six-month period ended on the same date. The company operates a facility in Oldsmar, Florida, and maintains international licensing agreements.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term indebtedness as of May 31, 2010. However, it owes a remaining balance of $95,457 to Red Rock for the acquisition of Safti-Cell, due in the third quarter of fiscal 2010. The company maintains a stockholders' deficit due to accumulated losses, though this deficit narrowed by approximately $771,000 during the period.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 5% ($440,081) compared to the prior year. This was driven by a 4% decrease in processing and storage fees (due to an 8% drop in specimens processed) and an 11% decrease in licensee income.
• Profitability Drop: Net income decreased by approximately 49% ($650,093). While cost of sales decreased by 2% due to operational efficiencies and the cancellation of the Safti-Cell contract, Marketing, General, and Administrative (MG&A) expenses increased by 7% ($290,917) due to increased sales initiatives.
• Cash Flow Reduction: Net cash provided by operating activities dropped significantly by 70% ($1,217,049), primarily due to lower net income and changes in working capital, specifically a decrease in deferred revenue growth compared to the prior year.
• Accounting Reclassifications: The company revised prior period financials (May 31, 2009) to reclassify licensee income from "other income" to "revenue" and to properly record foreign income tax expenses. These changes did not impact net income but improved revenue visibility.

Outlook, Risks, and Contingencies

• Guidance: Management anticipates funding future capital expenditures (approx. $500,000 over the next 12 months) with cash on hand and operating cash flows. They believe current resources are sufficient for the next 12 months.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of May 31, 2010. A material weakness regarding the accrual of licensee royalties was identified in the prior year. While remediation steps (restructuring agreements, adding staff) were implemented, the controls have not operated long enough to be deemed effective.
• Risks: Key risks include increased competition from public cord blood banks, potential government regulation of stem cell facilities, market acceptance of the new C'ellé service, and the financial stability of international licensees. The company also faces risks related to the valuation of its investment in Saneron CCEL Therapeutics, Inc.
• Contingencies: The company maintains a warranty program (Cryo-CellCares) with a reserve of approximately $10,862. No claims have been made to date. The company has no off-balance sheet arrangements.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of licensee income, which dropped 11% and is subject to the financial health of international partners.
• Internal Control Remediation: Monitor future filings to confirm when the material weakness regarding royalty accruals is officially remediated and controls are deemed effective.
• Expense Management: Assess whether the 7% increase in MG&A expenses yields a commensurate increase in new client enrollment to offset the decline in processing volume.
• Deferred Revenue: Review the $13.0 million in deferred revenue (current and long-term) to understand the runway for future revenue recognition.
• Saneron Investment: Evaluate the $684,000 investment in Saneron CCEL Therapeutics, Inc., which is recorded at goodwill value and subject to impairment testing.